Patents by Inventor Victor J. Dzau
Victor J. Dzau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040258669Abstract: The invention provides compositions and methods of enhancing the viability of primary stem cells and enhancing the engraftment of transplanted stem cells into a mammalian recipient. Accordingly, the invention includes a method of regenerating a mesenchymally-derived tissue by contacting the tissue with a composition containing an isolated adult mesenchymal stem cell, which are apoptosis-resistant. The mesenchymal stem cell is an adult cell obtained from an adult bone marrow.Type: ApplicationFiled: November 5, 2003Publication date: December 23, 2004Inventors: Victor J. Dzau, Abeel Mangi, James Edmund Ip
-
Patent number: 6821956Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: GrantFiled: April 19, 2001Date of Patent: November 23, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20040229833Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: May 20, 2004Publication date: November 18, 2004Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Patent number: 6774118Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: GrantFiled: September 8, 1995Date of Patent: August 10, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20040082659Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.Type: ApplicationFiled: July 15, 2003Publication date: April 29, 2004Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 6646006Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.Type: GrantFiled: February 1, 2002Date of Patent: November 11, 2003Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 6642208Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.Type: GrantFiled: August 15, 2001Date of Patent: November 4, 2003Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Publication number: 20030186922Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: April 25, 2003Publication date: October 2, 2003Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Patent number: 6579313Abstract: A method for implanting cells onto a prosthesis includes the steps of: (a) providing a prosthesis including a porous tube, where at least 25% of the pores on the inner surface of the tube have diameters of more than about 40 &mgr;m, at least 25% of the pores on the outer surface of the tube have diameters of less than about 30 &mgr;m, and the tube includes a substantially continuous layer of a biocompatible material; (b) contacting the prosthesis with a suspension of cells; and (c) providing a pressure differential between the inner surface and the outer surface, whereby the cells are retained in the pores of the inner surface. A method for obtaining an endothelial cell culture from a blood sample involved:(a) obtaining a sample for mononuclear cells from a blood sample; and (b) culturing the sample of mononuclear cells, without further cell separation, on a cell adhesive polymer-coated solid support in the presence of endothelial growth factors.Type: GrantFiled: January 18, 2002Date of Patent: June 17, 2003Assignee: The Bringham and Women's HospitalInventors: Victor J. Dzau, Richard E. Pratt, Michael J. Mann, Afshin Ehsan, Daniel P. Griese
-
Publication number: 20020151592Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds, namely L-arginine, L-lysine, physiologically acceptable salts thereof, and polypeptide precursors thereof, which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. In or in combination, other compounds, such as B.sub.6, folate, B.sub.12, or an antioxidant, which provide for short term enhancement of nitric oxide, either directly or by physiological processes may be employed.Type: ApplicationFiled: February 1, 2002Publication date: October 17, 2002Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. COOKE , Victor J. DZAU , Gary H. GIBBONS
-
Publication number: 20020128217Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signaling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: June 5, 2001Publication date: September 12, 2002Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20020091160Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.Type: ApplicationFiled: February 1, 2002Publication date: July 11, 2002Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Publication number: 20020058983Abstract: Disclosed herein is a method for implanting cells onto a prosthesis, including the steps of: (a) providing a prosthesis including a porous tube, where at least 25% of the pores on the inner surface of the tube have diameters of more than about 40 &mgr;m, at least 25% of the pores on the outer surface of the tube have diameters of less than about 30 &mgr;m, and the tube includes a substantially continuous layer of a biocompatible material; (b) contacting the prosthesis with a suspension of cells; and (c) providing a pressure differential between the inner surface and the outer surface, whereby the cells are retained in the pores of the inner surface. Also disclosed herein are methods for culturing cells for implantation.Type: ApplicationFiled: January 18, 2002Publication date: May 16, 2002Inventors: Victor J. Dzau, Richard E. Pratt, Michael J. Mann, Afshin Ehsan, Daniel P. Griese
-
Publication number: 20020052333Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: April 19, 2001Publication date: May 2, 2002Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Patent number: 6352555Abstract: Disclosed herein is a method for implanting cells onto a prosthesis, including the steps of: (a) providing a prosthesis including a porous tube, where at least 25% of the pores on the inner surface of the tube have diameters of more than about 40 &mgr;m, at least 25% of the pores on the outer surface of the tube have diameters of less than about 30 &mgr;m, and the tube includes a substantially continuous layer of a biocompatible material; (b) contacting the prosthesis with a suspension of cells; and (c) providing a pressure differential between the inner surface and the outer surface, whereby the cells are retained in the pores of the inner surface. Also disclosed herein are methods for culturing cells for implantation.Type: GrantFiled: July 8, 1999Date of Patent: March 5, 2002Assignee: The Brigham and Womens Hospital, Inc.Inventors: Victor J. Dzau, Richard E. Pratt, Michael J. Mann, Afshin Ehsan, Daniel P. Griese
-
Publication number: 20020013288Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.Type: ApplicationFiled: August 15, 2001Publication date: January 31, 2002Inventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 6337321Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.Type: GrantFiled: May 8, 1998Date of Patent: January 8, 2002Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 6294384Abstract: The present invention is directed to an isoform of the p53 tumor suppressor and to polynucleotides that encode this isoform. The isoform may be used as a marker to indicate that cardiac cells have experienced hypoxia, as would occur during a myocardial infarction. In addition, vectors encoding the isoform may be transfected into cells as a means of regulating proliferation.Type: GrantFiled: October 7, 1999Date of Patent: September 25, 2001Assignee: The Brigham and Women's Hospital Inc.Inventors: Giorgio Dell'Acqua, Michael J. Mann, Victor J. Dzau
-
Patent number: 5945452Abstract: Atherogenesis and restenosis are treated by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes. In addition, cells may be genetically engineered to provide a component in the synthetic pathway to nitric oxide, so as to drive the process to enhance nitric oxide concentration, particularly in conjunction with the administration of a nitric oxide precursor.Type: GrantFiled: February 7, 1997Date of Patent: August 31, 1999Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 5922687Abstract: Naked nucleic acids (DNA, RNA, and/or analogs), drugs, and/or other molecules in an extracellular environment enter cells in living intact tissue upon application of pressure to the cells and extracellular environment. Nucleic acids localize to the cell nuclei. Transfection efficiencies greater than 90% are achievable for naked DNA and RNA. A sealed enclosure, defined by an enclosing means and/or tissue, contains the cells and their extracellular environment. The enclosure is pressurized to an incubation pressure on the order of atmospheres. A protective inelastic sheath may be used to prevent distension and trauma in tissue that is part of the enclosure boundary. Suitable enclosures include pressurization chambers and organs such as blood vessels or the heart. Parts of organs, entire organs, and/or entire organisms are pressurized. Suitable target tissue types include blood vessel (in particular vein) tissue, heart, kidney, liver, and bone marrow tissue.Type: GrantFiled: November 7, 1996Date of Patent: July 13, 1999Assignee: Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael J. Mann, Frank P. Diet, Victor J. Dzau, Gary H. Gibbons, Heiko Von Der Leyen